The Coverage & Financing Challenge
Cell and gene therapies (CGTs) — treatments priced from $300,000 to more than $4 million per patient — are no longer hypothetical line items for employer plan sponsors. As of 2025, the FDA has approved 48 CGTs, and use within employment-based plans has grown from 7.9 per 100,000 enrollees in 2018 to 9.2 per 100,000 in 2022, with a much larger pipeline on the horizon. For self-insured employers — who represent 50–60% of all commercially insured workers — the arrival of a single claim can equal or exceed an entire year's benefits budget.
Benefit Design: Medical vs. Pharmacy Benefit
Employers must first decide how CGTs are classified within their plan. Because most approved therapies are administered in clinical or hospital settings, they are typically managed under the medical benefit. However, administration through the pharmacy benefit — via a pharmacy benefit manager (PBM) — may unlock better outcomes-tracking infrastructure, formulary controls, and access to rebate arrangements. Employers should audit plan document language to ensure CGTs are explicitly addressed, avoiding ambiguity that could trigger stop-loss disputes or coverage-denial appeals.
Prior Authorization and Utilization Management
A rigorous prior authorization (PA) process is essential. Employers should confirm that their utilization management (UM) vendor or third-party administrator (TPA) is current on FDA-approved indications, biomarker eligibility criteria, and Centers of Excellence (COE) requirements for each approved therapy.
Stop-Loss, Reinsurance, and Carve-Out Structures
Traditional specific stop-loss insurance remains the first line of defense, but several structural gaps have emerged. Carriers increasingly "laser" known high-risk members. Employers should review stop-loss contracts for gene therapy exclusions, no-new-laser clauses, and plan mirroring provisions before each renewal. Purpose-built gene therapy stop-loss products (e.g., CVS Caremark's Gene Therapy Stop-Loss, Cigna/Evernorth's Embarc® Benefit Protection, UnitedHealth/Optum Gene Therapy Risk Protection) offer fixed per-member-per-month (PMPM) premiums as a carve-out layer.
Outcomes-Based Contracts, Annuities, and Warranties
Value-based contracting is maturing, with three primary models in use: milestone-based rebates (full upfront payment with refunds if clinical thresholds are not met), warranty programs (administered by a third party), and performance-based installment payments (annuities that spread costs over multiple years). Employers can "stack" multiple strategies to address price, clinical uncertainty, and budget impact simultaneously.
Legal Considerations
Under the Employee Retirement Income Security Act of 1974 (ERISA), plan fiduciaries must act solely in the interest of participants with prudence and diligence. Excluding CGTs entirely triggers risks under the Americans with Disabilities Act (ADA) and the Genetic Information Nondiscrimination Act of 2008 (GINA). Employers should work with ERISA counsel before adopting any exclusion, cap, or restriction.
Employer Action Checklist
Benefit Design & Coverage Governance
- Audit plan documents and summary plan descriptions (SPDs) to confirm CGTs are explicitly included or excluded
- Decide whether CGTs will be managed under the medical benefit, pharmacy benefit, or via a carve-out arrangement
- Assign a benefits committee to review CGT coverage policy at least annually
- Consult ERISA counsel before implementing any CGT exclusion, dollar cap, or mid-year amendment
Stop-Loss & Reinsurance
- Review stop-loss contract language before each renewal for gene therapy exclusions and lasering provisions
- Negotiate no-new-laser clauses for newly eligible CGT candidates
- Evaluate purpose-built gene therapy stop-loss programs (CVS/Aetna, Cigna/Evernorth Embarc®, Optum) for PMPM cost-effectiveness
- Model multi-year scenarios for captive structures that account for multiple simultaneous CGT claims
Value-Based & Innovative Payment Models
- Assess whether milestone-based rebates, warranties, or installment (annuity) arrangements are operationally feasible
- Work with PBM, TPA, or a third-party administrator to negotiate outcomes-based arrangements (OBAs)
- Ensure stop-loss terms are compatible with installment payment arrangements
- Engage directly with manufacturers of therapies likely to affect your covered population
Legal & Compliance
- Document all CGT coverage decisions with written rationale reflecting fiduciary prudence under ERISA
- Assess ADA and GINA (Genetic Information Nondiscrimination Act) exposure before implementing diagnosis-specific restrictions
- Review Consolidated Appropriations Act (CAA) reporting obligations for CGT drug pricing transparency
- Establish a clear appeals and exceptions process for employees
Resource Library
The most comprehensive payer-facing analysis of gene therapy payment strategies, co-developed by the Institute for Clinical and Economic Review (ICER) and the New Drug Development Paradigms (NEWDIGS) FoCUS Project at Tufts University. Covers milestone-based rebates, warranties, performance-based installment payments, stop-loss, subscription models, and policy reform recommendations.
A data-driven analysis from the Employee Benefit Research Institute (EBRI) quantifying CGT utilization at 9.2 per 100,000 enrollees in 2022. CGT users account for ~0.5% of total plan spending. Highlights how employer size shapes financial exposure.
Harvard researchers develop a taxonomy of gene therapy payment mechanisms — installments, risk pools, reinsurance, price-volume agreements, expenditure caps, subscriptions, outcomes-based payments, warranties, and coverage with evidence development. Essential reference for benefits executives.
Practical employer-facing guide from the National Alliance of Healthcare Purchaser Coalitions (NAHPC) covering five sequential action steps. Includes sample employer strategy survey data and therapy costs ($300K–$3.5M).
Companion piece providing background on the CGT field — therapy types, the patient journey, and emerging care delivery models — to help benefits professionals build foundational literacy.
Foundational actuarial analysis showing how four-year installment contracts expose employers to 58% of costs versus 10% under upfront payment, due to standard 24/12 stop-loss agreements. Widely cited by benefits consultants.
Peer-reviewed companion to the ICER/NEWDIGS (Institute for Clinical and Economic Review / New Drug Development Paradigms) white paper. Provides a detailed comparison matrix of value-based contract types. Valuable for employers evaluating 'stacking' strategies.
Models projected per-person annual cost of covering all existing and expected CGTs at approximately $15.69 per person per year through 2035. Proposes innovative insurance intermediary models to democratize employer access to CGT financing tools.
Policy framework from USC proposing a stepwise approach to CGT financing reform — from private-market financial intermediation to publicly subsidized private coverage. Addresses why stop-loss alone cannot solve the CGT financing challenge.
Analyzes 200+ transformative therapy products in the pipeline. 89% will be administered in hospital settings. Discusses the Center for Medicare and Medicaid Innovation (CMMI) Cell & Gene Therapy Access Model.
Ongoing updates on Medicare CAR-T (Chimeric Antigen Receptor T-cell therapy) inpatient payment, New Technology Add-on Payment (NTAP) changes, and implications for commercial employer plan sponsors.
Addresses four key employer questions on risk exposure, coverage obligations, CGT management, and stop-loss implications. Notes 99–100% of commercial plan sponsors currently provide broad CGT coverage.
Covers legal risks of CGT exclusions (ADA discrimination, HIPAA violation risk for mid-year amendments), payment solutions, and medical vs. pharmacy benefit management decisions. Includes compliance checklist.
Focused update on gene therapy precertification and prior authorization processes. Guidance for plan sponsors on ensuring utilization management (UM) providers are current with FDA-approved indications.
Quantitative illustration of how a $2.5M CGT claim propagates through a captive insurance structure. Discusses gene therapy risk pools, specialized reinsurance carve-outs, and actuarial modeling challenges.
Product documentation covering 11 approved single-administration therapies at individual stop-loss levels of $30K, $250K, or $400K, priced at $0.85–$2.50 PMPM (per member per month). Useful for benchmarking purpose-built CGT stop-loss.
Evernorth's overview of gene therapy risk management including the Embarc® Benefit Protection program. Describes outcomes-based agreements (OBAs) available through Evernorth's contracting capabilities.
The Employee Benefits Security Administration's (EBSA's) authoritative guide to ERISA fiduciary responsibilities — loyalty, prudence, plan document adherence, and oversight of third-party administrators. Essential baseline for CGT coverage decisions.
Analyzes the landmark Johnson & Johnson class action and subsequent fiduciary duty litigation. Explains how ERISA's prudence and loyalty standards now require active oversight of PBM (Pharmacy Benefit Manager) arrangements.
Actuarial perspective on cost-sharing design, plan provisions, and benefit consultant considerations for CGT coverage. Covers how actuarial value thresholds and Essential Health Benefits (EHBs) under the Affordable Care Act (ACA) interact with self-insured plan design.
Comprehensive checklist covering plan document inclusion, certificate of coverage (COC) language, prior authorization protocols, biomarker testing, COE (Center of Excellence) network considerations, and risk pool participation. Particularly useful as a pre-renewal audit tool.
Addresses fragmentation risk when CGTs are carved out of integrated medical-pharmacy benefit structures. Estimates a 23% reduction in overall disease costs and $31 billion in savings over 10 years for certain covered therapies.
Policy priorities from the Purchaser Business Group on Health (PBGH). Includes clarifying antitrust guidance for joint purchasing, extending fiduciary obligations to PBMs (Pharmacy Benefit Managers) and TPAs (Third-Party Administrators), and supporting ERISA preemption of direct contracts.
Summary from the Academy of Managed Care Pharmacy (AMCP) Nexus conference crystallizing key reimbursement challenges for curative gene therapies. Emphasizes the role of managed care pharmacy in ensuring CGTs reach the right patients at the right providers.
Primary research from managed care payer interviews finding growing pressure from self-insured employers to control CGT costs. Provides direct quotes on stop-loss contract alignment and the role of Centers of Excellence for bleeding disorder CGTs.
No resources match your search. Try a different keyword or filter.
Disclaimer: This resource hub is provided for educational and informational purposes only. It does not constitute legal, actuarial, medical, or benefits advice. Employers should consult qualified ERISA counsel, benefits consultants, actuaries, and clinical advisors before making coverage, financing, or plan design decisions. All external links are provided for reference and do not imply endorsement.